Literature DB >> 31689280

177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation.

Majid Assadi1, Elahe Pirayesh2, Seyed Javad Rekabpour3, Farshad Zohrabi4, Esmail Jafari1, Iraj Nabipour5, Abdolhamid Esmaili6, Abdullatif Amini7, Hojjat Ahmadzadehfar8.   

Abstract

We presented a promising result of radionuclide therapy using Lu-PSMA and Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31689280     DOI： 10.1097/RLU.0000000000002824

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  3 in total

Review 1.  Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms.

Authors:  Amir Iravani; Ashwin Singh Parihar; Timothy Akhurst; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2022-06-03       Impact factor: 5.605

2.  Obstructive Jaundice: An Unusual Presentation of Neuroendocrine Differentiation in Prostatic Adenocarcinoma.

Authors:  Sampath Santhosh; Godwin Jeeva; Ranjan Kumar Mohapatra
Journal:  Indian J Nucl Med       Date:  2021-03-04

3.  The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.

Authors:  Frédéric Pouliot; Jean-Mathieu Beauregard; Fred Saad; Dominique Trudel; Patrick O Richard; Éric Turcotte; Étienne Rousseau; Stephan Probst; Wassim Kassouf; Maurice Anidjar; Félix Camirand Lemyre; Guillaume F Bouvet; Bertrand Neveu; Amélie Tétu; Brigitte Guérin
Journal:  BJU Int       Date:  2021-11-11       Impact factor: 5.969
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.